AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Scinai Immunotherapeutics Ltd. (SCNI) Soars 55.12% on Positive Publication
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jul 29, 2025 7:32 am ET1min read
Aime SummaryOn July 29, 2025,
Immunotherapeutics Ltd. (SCNI) experienced a significant surge, rising by 55.12% in pre-market trading, indicating a strong bullish sentiment among investors.Scinai Immunotherapeutics Ltd. recently announced a new peer-reviewed publication, which is likely to have contributed to the positive market sentiment. The company, specializing in inflammation and immunology biological products, has been making strides in the biopharmaceutical sector, which has garnered investor interest.
Additionally, Scinai Immunotherapeutics Ltd. has secured new funding and is expanding its contract development and manufacturing organization (CDMO) capabilities ahead of the BIO 2025 conference. This strategic move is expected to enhance the company's operational efficiency and market presence, further boosting investor confidence.
The company's recent extension to meet Nasdaq's equity and bid price standards has also been well-received by the market, as it provides Scinai with more time to stabilize its financial position and focus on growth initiatives.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet